Inflammatory Bowel Disease
An investigational anti-MAdCAM antibody was safe, well tolerated and superior to placebo for inducing remission in patients with moderate-to-severe ulcerative colitis in the phase 2 TURANDOT trial.
Preliminary results from this trial were previously shared at ECCO 2015 and DDW 2015, and have now been published in full in The Lancet.
This activity is supported by an educational grant from Receptos.
Digestive Disease Week
Search Healio's robust listing of national and international medical meetings.
©2017 All Rights Reserved.